Cargando…

Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review

Introduction The prognosis of anaplastic lymphoma kinase (ALK) fusion-positive metastatic non-small cell lung cancer (mNSCLC) patients has improved drastically since the introduction of targeted therapies. Apart from age, performance status, and type of driver mutation in a mNSCLC, prognosis also d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khaddar, Satvik, Kapoor, Akhil, Noronha, Vanita, Patil, Vijay M., Menon, Nandini, Mahajan, Abhishek, Janu, Amit, Kumar, Rajiv, Purandare, Nilendu, Prabhash, Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803546/ https://www.ncbi.nlm.nih.gov/pubmed/36588605 http://dx.doi.org/10.1055/s-0042-1742596

Ejemplares similares

ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario
por: Singh, Ajaykumar, et al.
Publicado: (2022)

Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
por: Kapoor, Akhil, et al.
Publicado: (2022)

Leptomeningeal metastasis from non-small cell lung cancer— a post-hoc analysis from four randomised clinical trials
por: Patil, Vijay, et al.
Publicado: (2022)

Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors
por: Kapoor, Akhil, et al.
Publicado: (2022)

Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2020)

Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings
por: Kapoor, Akhil, et al.
Publicado: (2022)

Small cell carcinoma of the oesophagus: experience of an Indian Tertiary Cancer Centre
por: Panda, Goutam Santosh, et al.
Publicado: (2022)

A real‐world data of Immune checkpoint inhibitors in solid tumors from India
por: Noronha, Vanita, et al.
Publicado: (2021)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
por: Noronha, Vanita, et al.
Publicado: (2020)

EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
por: Joshi, Amit, et al.
Publicado: (2017)

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country
por: Noronha, Vanita, et al.
Publicado: (2016)

Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
por: Tibdewal, Anil, et al.
Publicado: (2021)

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
por: Noronha, Vanita, et al.
Publicado: (2014)

Systemic therapy for limited stage small cell lung carcinoma
por: Noronha, Vanita, et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer
por: Patil, Vijay, et al.
Publicado: (2019)

ROS1 mutation non-small cell lung cancer—access to optimal treatment and outcomes
por: Joshi, Amit, et al.
Publicado: (2019)

Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1–5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial
por: Tibdewal, Anil, et al.
Publicado: (2021)

Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer
por: Patil, Vijay, et al.
Publicado: (2019)

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
por: Noronha, Vanita, et al.
Publicado: (2017)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
por: Joshi, Amit, et al.
Publicado: (2018)

Multidisciplinary brain metastasis clinic: is it effective and worthwhile?
por: Rajpurohit, Annu, et al.
Publicado: (2020)

Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer
por: Mahajan, Abhishek, et al.
Publicado: (2023)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer
por: Mahajan, Abhishek, et al.
Publicado: (2023)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Neoadjuvant chemotherapy in a rare type of very locally advanced sinonasal carcinomas – long-term results from a tertiary care centre
por: Saha, Saswata, et al.
Publicado: (2023)

Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre
por: Bondili, Suresh Kumar, et al.
Publicado: (2022)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

ALK1 Gene Rearranged Pulmonary Sarcomatoid Carcinoma Masquerading as Tuberculosis in a Young Male
por: Sahay, Ayushi, et al.
Publicado: (2021)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2019)

Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancer
por: Panda, Goutam Santosh, et al.
Publicado: (2022)

Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer
por: Noronha, Vanita, et al.
Publicado: (2016)

Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report
por: Abhishek, Mahajan, et al.
Publicado: (2022)

Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation—a phase 3 study
por: Joshi, Amit, et al.
Publicado: (2021)

Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma
por: Karn, Anukul, et al.
Publicado: (2021)

Real-world analysis of the use of lenvatinib in differentiated thyroid cancers
por: Peelay, Zoya, et al.
Publicado: (2023)

Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study
por: Patil, Vijay, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rccqskblv1mv1c8u4fk67npnk1